combination of azacitidine and trichostatin a decreased the tumorigenic potential of lung cancer cells

Clicks: 227
ID: 136504
2017
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #112 of 171 articles by views in jurnal tam

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 171 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Yang Yang,1,* Wei Yin,2,* Fengying Wu,3,* Jiang Fan1 1Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China; 2Key Laboratory of Oral Biomedical Engineering of Ministry of Education, Hospital of Stomatology, School of Stomatology, Wuhan University, Wuhan, China; 3Oncology Department, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China *These authors contributed equally to this work Purpose: This study aims to investigate the possibility of using epigenetic inhibitors against lung cancer. Methods: The changes in the proliferation of human lung cancer cells, NCI-H1975 and NCI-H1299 cells, treated with various doses of inhibitors of DNA methyltransferase (azacitidine [5-AZA]) or histone deacetylase inhibitors (trichostatin A [TSA]) were determined by cell counting. The cell viability of NCI-H1975 and NCI-H1299 cells treated with 5-AZA and/or TSA was measured by the MTT assay. The changes in expression of the AKT signaling pathway molecules caused by the application of 5-AZA and TSA were analyzed through their protein and mRNA levels. A xenograft model was used to observe the effects of 5-AZA and TSA on tumor growth in vivo. Results: 5-AZA and TSA inhibited the proliferation and viability of NCI-H1975 and NCI-H1299 cells. Their joint application significantly influenced the expression of key molecules in AKT signaling pathway in vitro, and inhibited the growth of xenograft tumors in vivo. Furthermore, TSA and 5-AZA decreased the tumorigenic ability of NCI-H1975 cells in vivo. Conclusion: The decreased cell viability and tumorigenic ability, as well as increased anti-oncogene expression following the joint application of 5-AZA and TSA, make these epigenetic inhibitors prospective therapeutic agents for lung cancer. Keywords: lung cancer, epigenetic inhibitor, azacitidine (5-AZA), trichostatin A
Reference Key
y2017oncotargetscombination Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yang Y, Yin W, Wu FY, Fan J
Are you one of these authors? Claim your profile
Journal jurnal tam
Year 2017
DOI
DOI not found
URL
https://www.dovepress.com/combination-of-azacitidine-and-trichostatin-a-decreased-the-tumorigeni-peer-reviewed-article-OTT
Keywords
lung cancer Oncology including cancer and carcinogens tumors

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.